Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment

(2013) A. Flint et al.   DIABETES OBESITY & METABOLISM

Alterations in energy balance following exenatide administration

(2012) David P. Bradley et al.   Applied Physiology Nutrition and Metabolism

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets

(2012) J. H. DeVries et al.   DIABETES CARE

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes

(2012) Michael Horowitz et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Elevated Amylase and Lipase Levels in Patients Using Glucagonlike Peptide-1 Receptor Agonists or Dipeptidyl-Peptidase-4 Inhibitors in the Outpatient Setting

(2012) Howard Lando et al.   Endocrine Practice

The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients

(2011) Anne Flint et al.   ADVANCES IN THERAPY

The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen

(2011) Christoph Kapitza et al.   ADVANCES IN THERAPY

Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes

(2011) J. Dushay et al.   DIABETES CARE

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

(2011) A Astrup et al.   INTERNATIONAL JOURNAL OF OBESITY

Liraglutide in clinical practice: dosing, safety and efficacy

(2010) G. E. Peterson et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus

(2009) Joshua J Neumiller et al.   ANNALS OF PHARMACOTHERAPY

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies

(2009) L. Blonde et al.   DIABETES OBESITY & METABOLISM

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET